MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$145.37
−2.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.2B | 1.9B | 3.2B | 6.8B | 18.9B |
| Cost of Revenue | 2.5B | 868.0M | 1.5B | 4.7B | 5.4B |
| Gross Profit | (280.0M) | 1.1B | 1.7B | 2.2B | 13.5B |
| Operating Expenses | |||||
| R&D Expense | 2.9B | 3.1B | 4.5B | 4.8B | 3.3B |
| SG&A Expense | 965.0M | 1.0B | 1.2B | 1.5B | 1.1B |
| General & Admin Expense | — | — | 1.0B | 1.3B | 1.0B |
| Selling & Marketing Expense | — | — | 146.0M | 204.0M | 121.0M |
| Other Expenses | (801.0M) | — | (37.0M) | — | (388.0M) |
| Total Operating Expenses | 3.0B | 4.2B | 5.7B | 6.4B | 4.0B |
| Cost and Expenses | 5.5B | 5.0B | 7.1B | 11.1B | 9.5B |
| Operating Income (EBIT) | (3.3B) | (3.1B) | (3.9B) | (4.2B) | 9.4B |
| Non-Operating | |||||
| Interest Income | 282.0M | 314.0M | 425.0M | 421.0M | 200.0M |
| Interest Expense | 25.0M | 10.0M | 24.0M | 38.0M | 29.0M |
| Net Interest Income | 257.0M | 304.0M | 401.0M | 383.0M | 171.0M |
| Other Non-Op Income/Expense | 233.0M | 306.0M | 338.0M | 297.0M | 155.0M |
| Non-Operating Income (excl Interest) | (250.0M) | (306.0M) | (362.0M) | (335.0M) | (184.0M) |
| EBT (Pre-Tax Income) | (3.1B) | (2.8B) | (3.6B) | (3.9B) | 9.6B |
| Income Tax Expense | 64.0M | 54.0M | (46.0M) | 772.0M | 1.2B |
| Bottom Line | |||||
| Net Income | (3.2B) | (2.8B) | (3.6B) | (4.7B) | 8.4B |
| Earnings from Cont. Ops | (3.2B) | (2.8B) | (3.6B) | (4.7B) | 8.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.2B) | (2.8B) | (3.6B) | (4.7B) | 8.4B |
| Per Share | |||||
| Basic EPS | ($7.98) | ($7.26) | ($9.27) | ($12.34) | $21.26 |
| Diluted EPS | ($7.98) | ($7.26) | ($9.27) | ($12.34) | $20.10 |
| Revenue Per Share | $5.63 | $5.00 | $8.33 | $17.93 | $47.91 |
| Shares | |||||
| Basic Shares Outstanding | 396.0M | 389.0M | 384.0M | 382.0M | 394.0M |
| Diluted Shares Outstanding | 396.0M | 389.0M | 384.0M | 382.0M | 416.0M |
| Profitability Metrics | |||||
| EBITDA | (2.8B) | (2.6B) | (3.4B) | (3.3B) | 10.0B |
| D&A | 241.0M | 215.0M | 189.0M | 621.0M | 348.0M |
| EBIT | (3.1B) | (2.8B) | (3.6B) | (3.9B) | 9.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026